Otros idiomas Crinetics Pharmaceuticals, Inc.

Acciones

CRNX

US22663K1079

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
42,12 ^USD	-0,40 %		-1,98 %	+18,38 %

17/04	Un iniciado de Crinetics Pharmaceuticals vendió acciones por valor de 639.256 dólares, según un reciente registro de la SEC	MT
26/03	Un iniciado de Crinetics Pharmaceuticals vendió acciones por valor de 1.433.675 dólares, según un reciente registro de la SEC	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing	17/04
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	11/04
Crinetics Pharmaceuticals Insider Sold Shares Worth $1,433,675, According to a Recent SEC Filing	26/03
Crinetics Pharmaceuticals Insider Sold Shares Worth $664,763, According to a Recent SEC Filing	22/03
Crinetics Pharmaceuticals Insider Sold Shares Worth $2,648,150, According to a Recent SEC Filing	22/03
Crinetics Pharmaceuticals Insider Sold Shares Worth $449,793, According to a Recent SEC Filing	21/03
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	19/03
Correction: Crinetics Pharmaceuticals Says Phase 3 Trial for Acromegaly Treatment Meets Endpoints; Shares Rise Pre-Bell	19/03
Crinetics Pharmaceuticals Says Phase 3 Trial for Acromegaly Treatment Meets Endpoints; Shares Rise Pre-Bell	19/03
Crinetics Pharmaceuticals : Topline Results from Paltusotine Phase 3 PATHFNDR-2 Study	19/03
Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study	19/03
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients	19/03
Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly	19/03
Crinetics Pharmaceuticals Up in Extended Hours After Positive Top-Line Results for Drug Candidate	12/03
Crinetics Pharmaceuticals : Presents Data from Phase 2 Study of Paltusotine in Carcinoid Syndrome	12/03
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome	12/03
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome	12/03
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	11/03
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	11/03
Crinetics Pharmaceuticals, Inc. announced that it has received $350.000028 million in funding from a group of investors	01/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Crinetics Pharmaceuticals, Inc.

Acciones

CRNX

US22663K1079

Otros idiomas

Filtros